Harlan Robins Sells 14,233 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 14,233 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $16.52, for a total transaction of $235,129.16. Following the completion of the transaction, the insider owned 1,155,291 shares in the company, valued at $19,085,407.32. This represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT traded up $0.36 during trading on Wednesday, hitting $16.44. 1,333,806 shares of the company were exchanged, compared to its average volume of 1,718,538. The firm’s 50 day moving average price is $16.85 and its 200-day moving average price is $15.79. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76. The stock has a market capitalization of $2.53 billion, a P/E ratio of -41.10 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same period last year, the business earned ($0.23) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ADPT. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new stake in Adaptive Biotechnologies during the fourth quarter worth about $28,000. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $30,000. EverSource Wealth Advisors LLC raised its holdings in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. grew its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Company reported a quarterly earnings beat with strong revenue growth (revenue up ~51% YoY), which underpins the stock’s positive momentum. MarketBeat ADPT summary
• Positive Sentiment: Several sell-side firms raised price targets or reiterated Buy/Overweight ratings (Guggenheim, JPMorgan, Piper Sandler, Wall Street Zen), giving investors analyst support for higher valuations. Analyst coverage summary
• Neutral Sentiment: Reported short-interest entries show 0 shares (days-to-cover 0.0) — this appears to be a data error or non-material and shouldn’t be interpreted as meaningful short activity. (No actionable link.)
• Neutral Sentiment: Small institutional activity: several funds reported modest new or increased positions in the fourth quarter; institutional ownership remains high (~99%), so movements are incremental. MarketBeat ownership note
• Negative Sentiment: CEO Chad Robins executed multiple large sales in late Feb–early Mar (including 53,083 shares on Mar 3 and larger blocks on Mar 2 and Feb 27), reducing his stake materially; large insider sales can create short-term selling pressure or raise governance/insider-confidence questions. Chad Robins sale alert
• Negative Sentiment: Director/insider Harlan S. Robins also sold smaller blocks (10,000 and 14,233 shares on Mar 2–3), further increasing headline insider selling volume. Harlan S. Robins filings

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.